세계의 수혈 진단 시장 : 시장 규모(컴포넌트별, 용도별, 최종사용자별, 지역별), 예측

Blood Transfusion Diagnostics Market Size and Forecast

Blood Transfusion Diagnostics Market size was valued at USD 5.64 Billion in 2024 and is projected to reach USD 10.33 Billion by 2032, growing at a CAGR of 7.86% from 2026 to 2032.

Blood transfusion diagnostics include several key tests and procedures designed to assure the safety and compatibility of blood transfusions. These tests assist in determining the optimal match between donor and recipient blood types reducing the danger of potentially fatal transfusion reactions. The key tests are blood typing which identifies ABO and Rh blood groups and cross-matching which confirms compatibility between the donor's and recipient's blood.

These diagnostics are critical for guaranteeing the safety and efficacy of blood transfusions, particularly blood typing, cross-matching, and infectious disease testing. Blood typing is essential for identifying the donor and recipient's blood groups (ABO and Rh) and preventing transfusion-related complications. Cross-matching tests ensure greater compatibility between donor and recipient blood lowering the likelihood of problems.

The future usage of blood transfusion diagnostics is projected to evolve in tandem with technological advancements, improving testing speed, accuracy, and safety. Molecular diagnostics, such as nucleic acid testing (NAT), are gaining popularity allowing for earlier detection of pathogens at lower doses, hence enhancing transfusion safety.

Global Blood Transfusion Diagnostics Market Dynamics

The key market dynamics that are shaping the global blood transfusion diagnostics market include:

Key Market Drivers:

Rising Blood Transfusion Demand: One of the key factors is the increased need for blood transfusions as chronic diseases, trauma cases, surgeries, and emergency treatment become more common. Conditions such as cancer, cardiovascular disease, and anemia frequently necessitate repeated transfusions increasing the necessity for comprehensive diagnostic technologies to ensure blood safety and compatibility.

Technological Advancements: Innovations in diagnostic technology are driving market expansion. The use of automated technologies, nucleic acid testing (NAT), and next-generation sequencing has improved the accuracy, speed, and reliability of blood tests. These developments reduce human error, improve the detection of blood-borne diseases, and provide improved results in blood compatibility testing resulting in increased demand for advanced diagnostic instruments.

Stringent Safety Regulations: Governments and health organizations impose stringent safety requirements to reduce transfusion-related consequences such as hemolytic responses and the spread of infectious infections. These requirements require complete screening of donated blood necessitating the use of modern diagnostics such as reagents, devices, and software, to ensure compliance.

Key Challenges:

Stringent Regulatory Requirements: Blood transfusion diagnostics are subject to stringent regulatory requirements from health authorities such as the FDA, EMA, and other international regulatory bodies. These rules necessitate significant clinical investigations and safety validations which might delay product approval and market introduction.

Diagnostic Tool Costs: Advanced diagnostic equipment, particularly devices equipped with cutting-edge technology such as molecular diagnostics and nucleic acid testing can be prohibitively expensive. These expenses can be prohibitive for smaller healthcare facilities, especially in low- and middle-income nations. The price of these technologies and the reagents necessary for frequent use limits their widespread acceptance presenting barriers to access in resource-constrained places.

Blood Supply Shortages: The efficacy of blood transfusion diagnostics is contingent on the availability of safe and compatible blood supplies. However, blood shortages caused by insufficient donors or logistical challenges during collection and storage can risk the diagnostic process.

Key Trends:

Technological Advancements: The incorporation of sophisticated technology such as automated analyzers and molecular diagnostics is altering blood transfusion diagnosis. Automated solutions increase the speed and accuracy of blood typing and pathogen detection, lowering human error and increasing lab workflow efficiency.

Growing Demand for Blood Components: As chronic diseases, surgical operations, and trauma cases become more common, so does the demand for blood transfusions around the world. This trend emphasizes the need for effective blood transfusion diagnostics to assure safe and compatible blood products. Healthcare professionals are increasingly focused on comprehensive testing standards to manage the growing patient population that requires blood transfusions.

Regulatory Compliance and Safety Standards: Regulatory bodies are enforcing stronger rules to assure the safety and efficacy of blood transfusion procedures. These requirements require comprehensive diagnostic testing which increases the demand for high-quality reagents, kits, and instruments. As compliance requirements become increasingly stringent, healthcare facilities invest in dependable diagnostic solutions to achieve these safety standards.

Global Blood Transfusion Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global blood transfusion diagnostics market:

North America:

The North American leads the blood transfusion diagnostics market due to its advanced healthcare infrastructure and high healthcare spending. Canada and Mexico both contribute significantly to market growth to a lesser level. The American Cancer Society estimates that 1.9 million new cancer cases will be identified in the United States in 2021 with many requiring blood transfusions during treatment.

According to the American Red Cross, the United States requires roughly 29,000 units of red blood cells every day. Another important driver is the increasing number of surgical procedures. The aging population also helps to drive market growth as older people are more likely to require blood transfusions. According to the United States Census Bureau, by 2030, all baby boomers will be over the age of 65, bringing the total elder population to 73 million people.

Blood transfusion diagnostics have improved in terms of safety and efficiency thanks to technological breakthroughs such as nucleic acid amplification testing (NAT). The FDA states that NAT can detect HIV 10 to 14 days sooner than previous antibody tests, considerably lowering the risk of transfusion-transmitted infections.

Asia Pacific:

The Asia Pacific blood transfusion diagnostics market is expanding rapidly with the area emerging as the fastest-growing market internationally. This acceleration is mostly due to the increasing population, rising prevalence of chronic diseases, and improved healthcare infrastructure in nations such as China and India. According to the World Health Organization, the prevalence of diabetes in the Western Pacific region, which includes many Asian countries, is anticipated to rise by 57%, from 131 million in 2021 to 206 million in 2045.

This growth in chronic diseases frequently needs blood transfusions, increasing the demand for diagnostic technologies. Furthermore, the growing number of surgical procedures in the region supports market expansion. According to World Bank data, current health expenditure per capita in East Asia and the Pacific has increased by 75%, from $571 in 2010 to $1,001 in 2019. This increased funding has resulted in better-equipped hospitals and blood banks accelerating the implementation of modern blood transfusion testing technology.

Furthermore, government attempts to improve blood safety are driving market expansion. For example, the National AIDS Control Organization (NACO) in India reported that HIV screening of given blood units has increased from 80% in 2007 to 100% in subsequent years, demonstrating the growing importance of blood safety procedures.

Global Blood Transfusion Diagnostics Market: Segmentation Analysis

The Global Blood Transfusion Diagnostics Market is segmented based on Component, Application, End-User, and Geography.

Blood Transfusion Diagnostics Market, By Component

• Reagents & Kits
• Instruments
• Software & Services

Based on the Component, the Global Blood Transfusion Diagnostics Market is bifurcated into Reagents & Kits, Instruments, and Software & Services. Reagents & Kits dominate the global blood transfusion diagnostics market due to their essential role in conducting blood typing, disease screening, and cross-matching tests. These consumables are in constant demand as they are critical for every transfusion procedure regardless of the equipment used. Reagents & kits are used across various healthcare settings including hospitals, blood banks, and diagnostic laboratories ensuring consistent market demand. Additionally, the frequent use and shorter shelf life of reagents and kits drive repeat purchases further boosting their market dominance.

Blood Transfusion Diagnostics Market, By Application

• Blood Grouping
• Disease Screening

Based on the Application, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Grouping and Disease Screening. In the global blood transfusion diagnostics market, disease screening is the dominant application. This is primarily driven by the critical need to ensure the safety of blood transfusions by screening for infectious diseases such as HIV, hepatitis, syphilis, and others. With stringent safety regulations in place, disease screening has become a priority to prevent the transmission of infections through blood transfusions. Additionally, advancements in testing technologies such as nucleic acid testing (NAT) have enhanced the ability to detect pathogens with greater accuracy and speed.

Blood Transfusion Diagnostics Market, By End-User

• Blood Banks
• Hospitals
• Diagnostic Laboratories

Based on the End-User, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Banks, Hospitals, and Diagnostic Laboratories. Hospitals are the dominant end-user in the blood transfusion diagnostics market due to their critical role in administering blood transfusions. Hospitals handle a wide range of medical conditions including surgeries, trauma care, and chronic diseases where blood transfusions are frequently required. As a result, they maintain a constant demand for accurate and timely blood transfusion diagnostics to ensure patient safety and effective treatment outcomes. Additionally, hospitals have integrated diagnostic facilities and blood banks that allow for seamless testing, cross-matching, and transfusion services.

Blood Transfusion Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Blood Transfusion Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global blood transfusion diagnostics market primarily due to the well-established healthcare infrastructure and the high demand for advanced diagnostic technologies. The region's strong presence of major diagnostic companies such as Abbott Laboratories and Ortho Clinical Diagnostics, drives innovation and adoption of cutting-edge blood testing methods. Additionally, North America has a robust blood donation system and stringent regulations ensuring the safety of transfusions which boosts demand for accurate diagnostic tools. The increasing prevalence of chronic diseases, surgical procedures, and trauma cases further elevates the need for reliable blood transfusion diagnostics.

Key Players

The "Global Blood Transfusion Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Grifols, Bio-Rad Laboratories, Immucor, Ortho Clinical Diagnostics, Quotient Limited, Roche Diagnostics, Haemonetics, Terumo BCT, and Beckman Coulter.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Transfusion Diagnostics Market Key Developments

• In November 2023, Grifols announced the Grifols sCD38 solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients.
• In March 2022, Mylab Discovery Solutions Pvt. Ltd. launched the NATSpert ID tripleH detection kit, san RT-PCR test that detects infection in given blood.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY COMPONENT

• 5.1 Overview
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Software & Services

6 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY APPLICATIONS

• 6.1 Overview
• 6.2 Blood Grouping
• 6.3 Disease Screening

7 BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

• 7.1 Blood Banks
• 7.2 Hospitals
• 7.3 Diagnostic Laboratories

8 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Ortho clinical Diagnostics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 DiaSorin S.p. A
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Grifols
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 S.A., F.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Hoffmann-La Roche Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bio-Rad Laboratories
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Siemens Healthcare Private Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 Thermo Fisher Scientific Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 Beckman Coulter, Inc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1.1 Related Research